The inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009, OT-101) is a promising approach given that increased TGF-β2 levels in the serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis [7]. The gene discussed is TGFB2; the disease is pancreatic neoplasm.